Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Cross-sectional studies have documented that 2-10% of patients who are chronically infected with hepatitis C virus (HCV) are also positive for hepatitis B virus (HBV) surface antigen (HBsAg). Data related to HCV-HBV coinfection are lacking in Korea. This study evaluated the clinical characteristics, the treatment efficacy of peginterferon alfa plus ribavirin, and the changes induced by such treatment in HBV status in chronic hepatitis C (CHC) patients coinfected with HBV. Methods: Eighteen (2.37%) HBsAg-positive CHC patients were selected from among the 758 subjects from the K(G)yeonggi-Incheon Peginterferon alfa and ribavirin in chronic hepatitis C Treatment (KIPECT) study, which evaluated the treatment efficacy and safety of peginterferon alfa plus ribavirin in CHC patients. Data on changes in the status of HBV infections were obtained. Results: HCV genotype 1b was the most common (44%). The overall sustained virologic response rate was 72% in all patients, and 60% and 87.5% in genotypes 1 and 2, respectively. Two of the 18 patients were positive for HBeAg, and 15 had baseline HBV DNA level of less than 2,000 IU/mL. Two of the three whose levels exceeded this threshold showed no detectable DNA after treatment. After the completion of treatment, serum HBV DNA levels were increased in the two patients whose baseline HBV DNA levels were less than 2,000 IU/mL. Conclusions: The prevalence of HBV coinfection in CHC patients was 2.37% and most of the patients were inactive carriers. The treatment efficacy was similar to that of HCV mono-infection. Reactivation of HBV replication was observed in some patients after CHC treatment.
Abstract
Background/Aims: Cross-sectional studies have documented that 2-10% of patients who are chronically infected with hepatitis C virus (HCV) are also positive for hepatitis B virus (HBV) surface antigen (HBsAg). Data related to HCV-HBV coinfection are lacking in Korea. This study evaluated the clinical characteristics, the treatment efficacy of peginterferon alfa plus ribavirin, and the changes induced by such treatment in HBV status in chronic hepatitis C (CHC) patients coinfected with HBV. Methods: Eighteen (2.37%) HBsAg-positive CHC patients were selected from among the 758 subjects from the K(G)yeonggi-Incheon Peginterferon alfa and ribavirin in chronic hepatitis C Treatment (KIPECT) study, which evaluated the treatment efficacy and safety of peginterferon alfa plus ribavirin in CHC patients. Data on changes in the status of HBV infections were obtained. Results: HCV genotype 1b was the most common (44%). The overall sustained virologic response rate was 72% in all patients, and 60% and 87.5% in genotypes 1 and 2, respectively. Two of the 18 patients were positive for HBeAg, and 15 had baseline HBV DNA level of less than 2,000 IU/mL. Two of the three whose levels exceeded this threshold showed no detectable DNA after treatment. After the completion of treatment, serum HBV DNA levels were increased in the two patients whose baseline HBV DNA levels were less than 2,000 IU/mL. Conclusions: The prevalence of HBV coinfection in CHC patients was 2.37% and most of the patients were inactive carriers. The treatment efficacy was similar to that of HCV mono-infection. Reactivation of HBV replication was observed in some patients after CHC treatment.
참고문헌 (31)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Ghany MG, "American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update", Hepatology, 49, pp.1335~1374 (2009)
- Peters MG, "Special populations with hepatitis B virus infection", Hepatology, 49, pp.146~155 (2009)
- Chu CJ, "Hepatitis B virus", hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment, 2008, pp.23, 512~520
- Mohamed Ael S, "Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients", Hepatogastroenterology, 44, pp.1404~1406 (1997)
- Zarski JP, "Characteristics of patients with dual infection by hepatitis B and C viruses", J Hepatol, 28, pp.27~33 (1998)
- Fong TL, "The significance of antibody to hepatitis C virus in patients with chronic hepatitis B", Hepatology, 14, pp.64~67 (1991)
- Kirk GD, "The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa", Hepatology, 39, pp.211~219 (2004)
- Benvegnù L, "Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study", Cancer, 74, pp.2442~2448 (1994)
- Chiaramonte M, "Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis", Cancer, 85, pp.2132~2137 (1999)
- Senturk H, "Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers", Neth J Med, 66, pp.191~195 (2008)
- 이고은, "3개 대학병원 환자의 바이러스성 간염 검사에 대한 혈청학적 표지자의 역학조사", Annals of Laboratory Medicine, 25(1), pp.61~65 (2005), 대한진단검사의학회
- Lee KS, "Korean Association for the Study of the Liver Guideline Committee. Management of chronic hepatitis B", Korean J Hepatol, 13, pp.447~488 (2007)
- Park SH, "Efficacy and tolerability of peginterferon alfa plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea; a multi-center, retrospective, observational study", Korean J Hepatol, 16(3), pp.58~ (2010)
- The Korean Association for The Study of The Liver, "Treatment guidelines for chronic hepatitis C 2004", Korean J Hepatol, 10(6), pp.101~125 (2004)
- Yu E, "Korean Study Group for the Pathology of Digestive Diseases. Histologic grading and staging of chronic hepatitis: on the basis of standardized guideline proposed by the Korean Study Group for the Pathology of Digestive Diseases", Korean J Hepatol, 9, pp.42~46 (2003)
- Chen DS, "Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience", J Infect Dis, 162, pp.817~822 (1990)
- Liaw YF, "Role of hepatitis C virus in dual and triple hepatitis virus infection", Hepatology, 22, pp.1101~1108 (1995)
- Liu CJ, "Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections", J Formos Med Assoc, 104, pp.783~791 (2005)
- Liaw YF, "Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection", Gastroenterology, 126, pp.1024~1029 (2004)
- Liaw YF, "Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination", Infection, 19, pp.250~251 (1991)
- Liu CJ, "Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses", Gastroenterology, 136, pp.496~504 (2009)
- Yu JW, "Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus", Liver Int, 29, pp.1485~1493 (2009)
- Gordon SC, "Treatment of HBV", HCV coinfection: releasing the enemy within, 2009, pp.136, 393~396
- 윤현아, "만성 C형간염에서 페그인터페론과 리바비린 병합요법의 효과", Clinical and Molecular Hepatology, 14(1), pp.36~45 (2008), 대한간학회
- 이혁, "우리나라 만성 C형간염의 초치료를 위한 페그인터페론과 리바비린 병합요법", Clinical and Molecular Hepatology, 12(2006), pp.31~40 (2006), 대한간학회
- 강명주, "우리나라 만성 C형간염 환자에서 페그인터페론과 리바비린의 병합치료에 대한 효과", Clinical and Molecular Hepatology, 14(3), pp.318~330 (2008), 대한간학회
- Lee LP, "Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients", J Gastroenterol Hepatol, 22, pp.515~517 (2007)
- Donato F, "A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma", Int J Cancer, 75, pp.347~354 (1998)
- Cacciola I, "Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease", N Engl J Med, 341, pp.22~26 (1999)
- Fukuda R, "Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver", J Med Virol, 63, pp.220~227 (2001)